Patient Assistance Programs From Pulmozyme Access Solutions
The consequences to patients with financial concerns can be significant. Pulmozyme® Access Solutions can help. We offer several options to help cover the cost of Pulmozyme® (dornase alfa) Inhalation Solution for your eligible patients who are uninsured, have been denied coverage by their health plans, have concerns about co-pays or are worried about out-of-pocket expenses.
Ways we can help your patients who need access to Pulmozyme include:
- ThePulmozyme Access Solutions Co-Pay Card Program for eligible patients who have expressed concerns to your office about the cost of their co-pays.
- The Pulmozyme StarteRx Program for eligible patients initiating therapy while insurance coverage is established or the patient is changing plans
- The Genentech®Access to Care Foundation helps patients who are uninsured or who have been denied coverage for Pulmozyme by their health plans
- Referrals to independent, non-profit organizations for help with co-pays and out-of-pocket costs
At Pulmozyme Access Solutions, we can connect your patients to their medicine with ongoing support. We will work with you to overcome barriers to access and find solutions.
Pulmozyme (dornase alfa) Inhalation Solution Important Information
Indication and Usage
Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC 
40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.
Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.
For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF health care team.
Pulmozyme® is a registered trademark and the Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.
